Insulin analogues and severe hypoglycaemia in type 1 diabetes

P L Kristensen; L S Hansen; M J Jespersen; U Pedersen-Bjergaard; Henning Beck-Nielsen; J S Christiansen; K Nørgaard; H Perrild; Hans-Henrik Dyring Parving; B Thorsteinsson; Lise Tarnow

doi:10.1016/j.diabres.2011.10.046

Insulin analogues and severe hypoglycaemia in type 1 diabetes

P L Kristensen, L S Hansen, M J Jespersen, U Pedersen-Bjergaard, Henning Beck-Nielsen, J S Christiansen, K Nørgaard, H Perrild, Hans-Henrik Dyring Parving, B Thorsteinsson, Lise Tarnow

50 Citationer (Scopus)

Abstract

Introduction: The effect of insulin analogues on glycaemic control is well-documented, whereas the effect on avoidance of severe hypoglycaemia remains tentative. We studied the frequency of severe hypoglycaemia in unselected patients with type 1 diabetes treated with insulin analogues, human insulin, or mixed regimens. Methods: A questionnaire was posted from six Danish diabetes clinics to 6112 unselected patients with type 1 diabetes and filled in by 3861 patients (63.2%). Primary endpoint was number of episodes of severe hypoglycaemia in the preceding year. Mild hypoglycaemia was also reported. Results: The frequency of severe hypoglycaemic episodes per patient-year in patients receiving long-acting insulin analogues was 1.47. ±. 0.18 versus 1.09. ±. 0.10 in patients on long-acting human insulin (. p=. 0.01). The frequency of severe hypoglycaemic episodes per patient-year was 1.09. ±. 0.11 in patients on short-acting insulin analogues versus 1.26. ±. 0.13 in patients on short-acting human insulin (. p=. 0.15), which was statistically significant in an adjusted analysis. Conclusions: Severe hypoglycaemia is more frequent in patients with type 1 diabetes treated with long-acting insulin analogues. Confounding by indication may be involved. Clinical intervention trials using insulin analogues in patients prone to severe hypoglycaemia are highly needed.

Originalsprog	Engelsk
Tidsskrift	Diabetes Research and Clinical Practice
Vol/bind	96
Udgave nummer	1
Sider (fra-til)	17-23
Antal sider	7
ISSN	0168-8227
DOI	https://doi.org/10.1016/j.diabres.2011.10.046
Status	Udgivet - apr. 2012

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1016/j.diabres.2011.10.046

Citationsformater

@article{7ce073a83abc4531b82b7707d65a7521,

title = "Insulin analogues and severe hypoglycaemia in type 1 diabetes",

abstract = "Introduction: The effect of insulin analogues on glycaemic control is well-documented, whereas the effect on avoidance of severe hypoglycaemia remains tentative. We studied the frequency of severe hypoglycaemia in unselected patients with type 1 diabetes treated with insulin analogues, human insulin, or mixed regimens. Methods: A questionnaire was posted from six Danish diabetes clinics to 6112 unselected patients with type 1 diabetes and filled in by 3861 patients (63.2%). Primary endpoint was number of episodes of severe hypoglycaemia in the preceding year. Mild hypoglycaemia was also reported. Results: The frequency of severe hypoglycaemic episodes per patient-year in patients receiving long-acting insulin analogues was 1.47. ±. 0.18 versus 1.09. ±. 0.10 in patients on long-acting human insulin (. p=. 0.01). The frequency of severe hypoglycaemic episodes per patient-year was 1.09. ±. 0.11 in patients on short-acting insulin analogues versus 1.26. ±. 0.13 in patients on short-acting human insulin (. p=. 0.15), which was statistically significant in an adjusted analysis. Conclusions: Severe hypoglycaemia is more frequent in patients with type 1 diabetes treated with long-acting insulin analogues. Confounding by indication may be involved. Clinical intervention trials using insulin analogues in patients prone to severe hypoglycaemia are highly needed.",

author = "Kristensen, {P L} and Hansen, {L S} and Jespersen, {M J} and U Pedersen-Bjergaard and Henning Beck-Nielsen and Christiansen, {J S} and K N{\o}rgaard and H Perrild and Parving, {Hans-Henrik Dyring} and B Thorsteinsson and Lise Tarnow",

year = "2012",

month = apr,

doi = "10.1016/j.diabres.2011.10.046",

language = "English",

volume = "96",

pages = "17--23",

journal = "Diabetes Research and Clinical Practice",

issn = "0168-8227",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Insulin analogues and severe hypoglycaemia in type 1 diabetes

AU - Kristensen, P L

AU - Hansen, L S

AU - Jespersen, M J

AU - Pedersen-Bjergaard, U

AU - Beck-Nielsen, Henning

AU - Christiansen, J S

AU - Nørgaard, K

AU - Perrild, H

AU - Parving, Hans-Henrik Dyring

AU - Thorsteinsson, B

AU - Tarnow, Lise

PY - 2012/4

Y1 - 2012/4

N2 - Introduction: The effect of insulin analogues on glycaemic control is well-documented, whereas the effect on avoidance of severe hypoglycaemia remains tentative. We studied the frequency of severe hypoglycaemia in unselected patients with type 1 diabetes treated with insulin analogues, human insulin, or mixed regimens. Methods: A questionnaire was posted from six Danish diabetes clinics to 6112 unselected patients with type 1 diabetes and filled in by 3861 patients (63.2%). Primary endpoint was number of episodes of severe hypoglycaemia in the preceding year. Mild hypoglycaemia was also reported. Results: The frequency of severe hypoglycaemic episodes per patient-year in patients receiving long-acting insulin analogues was 1.47. ±. 0.18 versus 1.09. ±. 0.10 in patients on long-acting human insulin (. p=. 0.01). The frequency of severe hypoglycaemic episodes per patient-year was 1.09. ±. 0.11 in patients on short-acting insulin analogues versus 1.26. ±. 0.13 in patients on short-acting human insulin (. p=. 0.15), which was statistically significant in an adjusted analysis. Conclusions: Severe hypoglycaemia is more frequent in patients with type 1 diabetes treated with long-acting insulin analogues. Confounding by indication may be involved. Clinical intervention trials using insulin analogues in patients prone to severe hypoglycaemia are highly needed.

AB - Introduction: The effect of insulin analogues on glycaemic control is well-documented, whereas the effect on avoidance of severe hypoglycaemia remains tentative. We studied the frequency of severe hypoglycaemia in unselected patients with type 1 diabetes treated with insulin analogues, human insulin, or mixed regimens. Methods: A questionnaire was posted from six Danish diabetes clinics to 6112 unselected patients with type 1 diabetes and filled in by 3861 patients (63.2%). Primary endpoint was number of episodes of severe hypoglycaemia in the preceding year. Mild hypoglycaemia was also reported. Results: The frequency of severe hypoglycaemic episodes per patient-year in patients receiving long-acting insulin analogues was 1.47. ±. 0.18 versus 1.09. ±. 0.10 in patients on long-acting human insulin (. p=. 0.01). The frequency of severe hypoglycaemic episodes per patient-year was 1.09. ±. 0.11 in patients on short-acting insulin analogues versus 1.26. ±. 0.13 in patients on short-acting human insulin (. p=. 0.15), which was statistically significant in an adjusted analysis. Conclusions: Severe hypoglycaemia is more frequent in patients with type 1 diabetes treated with long-acting insulin analogues. Confounding by indication may be involved. Clinical intervention trials using insulin analogues in patients prone to severe hypoglycaemia are highly needed.

U2 - 10.1016/j.diabres.2011.10.046

DO - 10.1016/j.diabres.2011.10.046

M3 - Journal article

C2 - 22136722

SN - 0168-8227

VL - 96

SP - 17

EP - 23

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

IS - 1

ER -

Insulin analogues and severe hypoglycaemia in type 1 diabetes

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater